CD8A and melanoma: The success of immunotherapy using immune checkpoint blockers (ICBs) has been remarkable in boosting CD8+ T‐cell‐mediated antitumor immunity in the treatment of various solid tumors, including melanoma (Robert et al, 2015; Huang & Zappasodi, 2022).